A Phase 3 interventional study of PCV13i and Prevnar 13 in Pneumococcal Infections, Streptococcal Infections and Bacterial Infections, sponsored by CanSino Biologics Inc.. Active, not recruiting at 3 sites in Thailand. Open to participants aged 6 Weeks to 2 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by CanSino Biologics Inc. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pneumococcal Infections with a site in Thailand — 1 open to participants now, 3 under way, 3 of them phase 3. Pneumococcal Infections · Thailand.
Among the 11 studies in Pneumococcal Infections with a site in Thailand, this one is the 8th largest by enrollment, is one of 2 that started in 2025, is one of 11 in phase 3, and was the 10th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 11 studies in Pneumococcal Infections with a site in Thailand is open now. Recruiting first, the newest first:
Sanofi · Sites in Thailand, United States, Honduras and 1 more country
Ages 42 days–89 days · Healthy volunteers
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 6 Weeks to 2 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2025.
This study's enrollment of 600 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 882 across the 11 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 4 most frequent:
CanSino Biologics Inc. is the lead sponsor of 41 studies on the registry; 6 are open to participants now.
CanSino Biologics Inc. has 5 studies filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Pneumococcal Infections with a site in Thailand that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07017777Phase 3CanSino Biologics Inc.A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) | 2027-02-15 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Pneumococcal Infections with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a 2+1 schedule (2 months, 4 months and 12-15 months). The trial will enroll approximately 600 healthy infants aged 2 months (at least 6 weeks) who will be randomly assigned in a 1:1 ratio to receive either the experimental or control vaccine, with 100 in each group (200 in total) randomized to subgroups and subject to additional immunogenicity assessments. All participants will be evaluated for solicited adverse events for 7 days and unsolicited adverse events for 30 days post each vaccination. Immunogenicity evaluation will be performed in all participants at baseline and post the booster dose, while the sub-cohort participants will be evaluated for post primary series immunogenicity additionally.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria for the first dose:
Individual termination criteria for subsequent doses:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intramuscular Injection, 0.5ml
Biological: PCV13i
Intramuscular Injection, 0.5ml
Biological: Prevnar 13
3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)
3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)
Proportion of participants achieving serotype-specific IgG antibody concentrations ≥ 0.35 µg/mL
Time frame: 30 days after the booster dose
Incidence of solicited local and systemic adverse events (AEs)
Time frame: Within 7 days after each dose of vaccination
Incidence of unsolicited adverse events
Time frame: Within 30 days after each dose of vaccination
The number of serious adverse events (SAEs)
Time frame: Through study completion, an average of 16-19 months
The geometric mean concentration (GMC) of Serotype-specific IgG in all participants
Time frame: Before vaccination and 30 days after the booster dose
Proportion of participants achieving serotype-specific IgG antibody concentrations ≥ 0.35 µg/mL in Sub-cohort A participants
Time frame: 30 days after the primary series
Proportion of participants achieving serotype-specific IgG antibody concentrations ≥ 0.35 µg/mL in Sub-cohort B participants
Time frame: Before the booster dose
The geometric mean concentration (GMC) of Serotype-specific IgG in Sub-cohort A participants
Time frame: 30 days after the primary series
The geometric mean concentration (GMC) of Serotype-specific IgG in Sub-cohort B participants
Time frame: Before the booster dose
Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 15 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.